BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21130868)

  • 1. Intracellular adaptor molecules and AR signalling in the tumour microenvironment.
    Reebye V; Frilling A; Habib NA; Mintz PJ
    Cell Signal; 2011 Jun; 23(6):1017-21. PubMed ID: 21130868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy.
    Burnstein KL
    J Cell Biochem; 2005 Jul; 95(4):657-69. PubMed ID: 15861399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y; Wolff DW; Lin MF; Tu Y
    Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.
    Taplin ME; Balk SP
    J Cell Biochem; 2004 Feb; 91(3):483-90. PubMed ID: 14755679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q; Titus MA; Fung KM; Lin HK
    J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
    Reddy GP; Barrack ER; Dou QP; Menon M; Pelley R; Sarkar FH; Sheng S
    J Cell Biochem; 2006 Aug; 98(6):1408-23. PubMed ID: 16619263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Castration-resistant prostate cancer: locking up the molecular escape routes.
    Attar RM; Takimoto CH; Gottardis MM
    Clin Cancer Res; 2009 May; 15(10):3251-5. PubMed ID: 19447877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.
    Sampson ER; Yeh SY; Chang HC; Tsai MY; Wang X; Ting HJ; Chang C
    J Biol Regul Homeost Agents; 2001; 15(2):123-9. PubMed ID: 11501969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collocation of androgen receptor gene mutations in prostate cancer.
    Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
    Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
    Wu JD; Haugk K; Woodke L; Nelson P; Coleman I; Plymate SR
    J Cell Biochem; 2006 Oct; 99(2):392-401. PubMed ID: 16639715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the androgen receptor in the development and progression of prostate cancer.
    Jenster G
    Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
    Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
    Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
    Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
    Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
    Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD; Lambert JR; Nordeen SK
    Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.